Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript)

Core Insights - Vertex Pharmaceuticals experienced exceptional growth in 2024, marked by financial performance, regulatory approvals, and the acquisition of Alpine Immune Sciences [3] - In 2025, the company continues to lead in cystic fibrosis (CF) with the recent approval and launch of ALYFTREK, and is building momentum with CASGEVY, a gene editing therapy for sickle cell disease and beta-thalassemia [3] - Vertex is also launching JOURNAVX to expand its franchise in acute pain, indicating a busy start to the year with four Phase 3 programs expected to have significant milestones [3][4]